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Glucosidase I (GI) removes the outermost glucose from pro-
tein-linked Glc3Man9GlcNAc2 (G3M9) in the endoplasmic
reticulum (ER). Individuals with congenital disorders of glyco-
sylation MOGS-CDG bear mutations in the GI-encoding gene
(gls1). AlthoughGI absencehas been reported toproduce lethal-
ity in Schizosaccharomyces pombe yeasts, here we obtained two
viable gls1mutants, one with a very sick but not lethal pheno-
type (gls1-S) and the other with a healthier one (gls1-H). The
sick strain displayed only G3M9 as an ER protein–linked oligo-
saccharide, whereas the healthier strain had both G3M9 and
Man9GlcNAc2. The lipid-linked oligosaccharide patterns of the
two strains revealed that themost abundantly formedglycanswere
G3M9 in gls1-S and Glc2Man9GlcNAc2 in gls1-H, suggesting
reduced Alg10p glucosyltransferase activity in the gls1-H strain.
Amutation in the alg10 gene was indeed observed in this strain.
Our results indicated that abrogated G3M9 deglucosylation was
responsible for the severedefects observed ingls1-S cells. Further
studies disclosed that the defects could not be ascribed to disrup-
tion of glycoprotein entrance into calnexin-folding cycles, inhibi-
tion of the oligosaccharyltransferase by transfer reactionproducts,
or reduced proteasomal degradation of misfolded glycoproteins.
Lackof triglucosylatedglycoproteindeglucosylationneithersignif-
icantly prevented glycan elongation in the Golgi nor modified the
overall cell wall monosaccharide composition. Nevertheless, it
resulted in adistorted cellwall and in the absenceof underlyingER
membranes. Furthermore, Golgi expression of human endoman-
nosidase partially restored normal growth in gls1-S cells. We
propose that accumulation of G3M9-bearing glycoproteins is
toxic and at least partially responsible for defects observed in
MOGS-CDG.
N-Glycans have multiple functions in the secretory pathway
as they influence protein folding in the ER5 and, after being
remodeled in the Golgi, mediate interactions among cells and
with the environment. It is not surprising then that genetic
defects resulting in either their absence in normally occupied
glycoprotein sites or in formation of aberrant N-glycan struc-
tures have a dramatic impact on many intra- and extracellular
functions.
N-Glycosylation is one of the most frequent post-transla-
tional modifications of proteins following the secretory path-
way. It starts with the initial en bloc transfer of glycan G3M96
(Fig. 1A) from a step-by-step prebuilt dolichol pyrophosphate
derivative (Dol-PP) to Asn residues in the consensus
sequence Asn-Xaa-Ser/Thr (XaaPro) in proteins entering
the ER. The reaction is catalyzed by the oligosaccharyltrans-
ferase (OST), a multimeric membrane complex (Fig. 1B)
(1–3). Addition of glycans facilitates per se protein folding as
it provides bulky hydrophilic groups that help keeping fold-
ing intermediates in solution.N-Glycan processing by glyco-
sidases and glucosyltransferases starts in the ER immediately
after glycan transfer. Glycan remodeling plays a determining
role in the mechanism of quality control of glycoprotein
folding (4). Briefly, the glycan G3M9 transferred to Asn res-
idues is first deglucosylated by GI, a type II membrane pro-
tein with a luminal hydrolytic domain that removes the out-
ermost Glc of the glycan (residue n, Fig. 1A). The G2M9 thus
produced is then deglucosylated by glucosidase II (GII) that
successively generates G1M9 and M9 by removing the
remaining glucose residues (l andm, Fig. 1A). G1M9 may be
regenerated fromM9 by the UDP-Glc:glycoprotein glucosyl-
transferase (UGGT), a protein conformation sensor that
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adds a Glc (residue l, Fig. 1A) exclusively to proteins that
have not yet acquired their native conformation (5, 6).
Monoglucosylated glycan-bearing glycoproteins produced
either by de-glucosylation of the transferred glycan or by
re-glucosylation by UGGT may interact with calnexin
(CNX) and/or calreticulin, two ER-resident lectin chaper-
ones that specifically recognize monoglucosylated struc-
tures. Glycoprotein–lectin interactions enhance folding effi-
ciency and allow participation of a protein-disulfide protein
isomerase (ERp57) in the folding process. In addition, they
prevent Golgi exit of folding intermediates and irreparably
misfolded glycoproteins (Fig. 1B). Cycles of glucosylation
and deglucosylation catalyzed by the opposite activities of
UGGT and GII continue until proper folding is achieved
(Fig. 1B) (4). Folded glycoproteins pursue their transit
through the secretory pathway where their glycans are fur-
ther modified in the Golgi. Irreversibly misfolded glycopro-
teins are demannosylated and eventually retrotranslocated
to the cytosol to be degraded in proteasomes in a process
known as ER-associated degradation (ERAD).
The congenital disorders of glycosylation (CDG) are a group
of more than 100 human inherited syndromes, most of them
(70%) produced by deficiencies in protein N-glycosylation
pathways (7). The clinical features of these disorders involve
many organ systems but are especially common in the nervous,
hepatic, visual, and immune systems. Patients display patholo-
gies that include delayed growth, developmental disabilities,
low muscle tone, visual problems, and incomplete brain devel-
opment. Type I CDG are caused by defects in the biosynthesis
of lipid-linked oligosaccharides (LLO) and their transfer to pro-
teins, whereas type II CDG are caused by defects in the glycan
processing of protein-linked oligosaccharides (NLO). The first
type results in glycoprotein hypoglycosylation (normally occu-
pied glycosylation sites are empty), but the remaining glycans
Figure 1. N-Glycosylation, N-glycan processing, and quality control of glycoprotein folding in the ER. A, synthesis and structure of glycan G3M9
transferred to proteins in N-glycosylation. The glycan is built in the ER membrane by the step by step addition of single monosaccharides to dolichol-P
following theorderof letters (a, b, c, d . . . ) by the indicatedALGglycosyltransferases. It starts at the cytoplasmic sideof theERmembrane, andonce the structure
Dol-PP-M5 is formed the glycan flips to the lumen of the ER where synthesis is completed. Arm A (residues d, f, g, and l–n), arm B (residues h and I), arm C
(residues j and k) of the glycan, sites of GI and GII trimming in the ER after transference, and site of expressed Golgi human endomannosidase trimming are
indicated. B, glycan transfer,N-glycan processing and ER quality control of glycoprotein folding. The last three steps of Dol-PP-G3M9 synthesis are shown. The
OST complex transfers theglycan to the consensus sequenceNX(S/T)(XP) of proteins entering into the ER through the Sec61 translocon.GI removesGlcn and
GII removes Glcm. Monoglucosylated glycans interact with CNX, which facilitates glycoprotein folding. GII removes Glc l and folded glycoproteins exit the ER.
Unfolded proteins are recognized byUGGT, which adds back Glc l. Glycoproteins that fail to properly fold after several reglucosylation–deglucosylation cycles
are demannosylated by ER -mannosidases (MAN), recognized then by lectin OS9, and retrotranslocated to the cytosol for degradation in proteasomes
(ERAD). Monosaccharide symbols follow the Symbol Nomenclature for Glycans (SNFG) system (49).
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have almost normal structures, and in the second type there is a
normal occupation of glycosylation sites, but the attached
glycans have abnormal structures (7). Regarding the type II
diseases, MOGS-CDG (also known as CDG-IIb) is produced
by mutations in GI, the enzyme responsible for the first step
in N-glycan processing (Fig. 1). The clinical course of the
disease is progressive and characterized by multiple neuro-
logical complications, severe hypogammaglobulinemia, hep-
atomegaly, hypoventilation, feeding problems, seizures, and
sometimes a fatal outcome (8, 9).
Contrary to the more commonly used yeast Saccharomyces
cerevisiae, which lacks UGGT, the fission yeast Schizosaccha-
romycespombehasconservedall componentsof theearlyN-gly-
cosylation steps and the quality control of glycoprotein folding
mechanism present in mammalian cells, and it has also been
extensively used as a model organism to study those processes
(4, 10). In an attempt to understand the role of GI in themolec-
ular bases of MOGS-CDG, we obtained two haploid strains of
the fission yeast S. pombe lacking the gene coding forGI (gls1).
Surprisingly, one of the strains showed a severe growth defect,
and the other displayed an almost normal growth rate.We then
analyzedNLO and LLOpatterns produced by both strains. Our
results suggest that a suppression of the mutant phenotype is
caused by a simultaneous mutation in the alg10 gene in the
strain that displayed a relieved growth rate. As the protein
encoded by that gene is responsible for the addition of the out-
ermost glucose to the Dol-PP derivative, we concluded that
accumulation of three Glc moieties in the newly synthesized
glycoproteins is the main cause of the growth defect in GI
mutants. We propose that at least part of the defects observed
in MOGS-CDG patients are caused by the accumulation of tri-
glucosylated glycoproteins.
Results
Knockout of GI-encoding gene produces severemorphological
and growth defects in the fission yeast S. pombe
According to an analysis of a genome-wide set of gene dele-
tions in the fission yeast S. pombe, deletion of the GI-encoding
gene (gls1 mutants) is apparently lethal (11). This is in con-
trast to what was reported for S. cerevisiae, in which mutants
lacking the GI-encoding gene are viable (12) but in agreement
with the report of patients in which mutations in GI-encoding
gene result in MOGS-CDG with severe and sometimes lethal
pathologies (8, 13). In an attempt to understand the role of GI
in MOGS-CDG, we induced meiosis and sporulation in a
heterozygousgls1/ diploid S. pombe strain.We were able to
obtain two viablegls1haploid strains that arose from spores of
the same tetrad (Fig. 2A). One of the strains (gls1-S) showed a
very sick but not lethal growth defect. Surprisingly, the other
strain (gls1-H), although genetically also a gls1 knockout
mutant, displayed a much healthier phenotype (Fig. 2B). We
compared the growth-rate parameters in rich liquidmedium of
bothgls1mutantswith that ofWT and recorded that although
the sick gls1-S strain had all the growing parameters altered,
i.e. an 8 times longer lag phase (32 h versus 4 h, p  0.005), a
4-fold increase in the duplication time at the middle of the
exponential phase (p 0.027), and half the maximal A600 nm at
the stationary phase (p  0.045), the same growth parameters
of the healthier gls1-H strain were significantly improved,
with a shorter lag time (8 h), a duplication time twice as fast
than that of gls1-S strain (p  0.045), and only a moderate
reduction in the cell density at the stationary phase (Table S1).
Complementation of the sickgls1-Smutantwith gene gls1
restored a normal growth phenotype, indicating that the
absence of such gene was responsible for the observed defect in
themutant (Fig. 2C). Thegls1-Smutants cells observed under
the microscope showed an aberrant morphology, with a
reduced size and a rounded shape that tended to clump when
compared with both WT and the healthier gls1-H cells, sug-
gesting that some kind of suppression had occurred in the last
strain (Fig. 2D) (14).
NLO and LLO produced bygls1mutants
To understand the phenotypic differences between both
gls1 sick and healthier mutants, we first inspected the differ-
ences in the NLOs produced in vivo in the ER byWT, gls1-S,
andgls1-H strains. Cells were labeled for 15minwith [14C]Glc
in the absence of any glucosidase inhibitor and in the presence
of 5mMDTT to preclude glycoprotein ER exit.WT cells rapidly
trimmed protein-linked glycans from the transferred G3M9
structure to M9 by the sequential action of GI and GII (Fig. 3A
and see Fig. 1). The severely affected gls1-S cells showed the
N-glycan pattern expected for a gls1mutant, as these mutant
cells are unable to hydrolyze the transferred G3M9 glycans
and thus accumulate such structures (Fig. 3B). However, the
healthiergls1-H cell glycan pattern showed a furtherN-gly-
can processing to M9 (Fig. 3C), which was delayed when GI
and GII were partially inhibited upon addition of castano-
spermine (CST) andN-methyl-deoxynojirimycin (NM-DNJ)
(Fig. 3D).
gls1-H strain showed a significant amount of glucose-free
NLOs containing nine Man units similar to those produced by
Figure 2. Lack of GI-encoding gene (gls1) produces severe growth and
morphological defects in S. pombe. A, genomic characterization of
S. pombe gls1-S and gls1-H strains. PCRs were performed using primers
that hybridize inside and outside the knockout insertion cassette (NatMX fw
and gls1–3NC, respectively) and the indicated boiled yeast sister colonies as
DNA template. B, growth of S. pombeWT,gls1-S, andgls1-H in solidmedia.
WT andmutant cells were grownup toA600 nm 1, and drops (5l) of 10-fold
dilutionswere plated on YES. Plateswere incubated 72 h at 28 °C.C, reversion
of the sick phenotype of gls1-S cells by complementation with gls1 gene.
Competent gls1-S cells were transformed either with vector alone or with
vector carrying gls1 gene. Leu arising transformants were streaked in MM
supplementedwith adenine and uracil and grown for 72 h.D,morphology of
gls1-S and gls1-H mutants. Yeast cultures at A600 nm  1 were observed
under a transmission microscope with a100 objective. Bar, 10 m.
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WT cells. This result cannot be explained by either a partial
activity of GI, as the knockout strain has a large coding-se-
quence deleted, or by the presence of another GI-like activity in
the ER (15). We hypothesized that the unexpected N-glycan
pattern observed in gls1-H strain could be explained by an
incomplete LLO synthesis. Thus, we analyzed the LLO pattern
synthesized in vivo by WT and gls1-H mutant cells. As
expected, almost allWT LLOs had a G3M9 structure (Fig. 4A).
However, in gls1-H mutant cells G2M9 was the main LLO
present (Fig. 4B). The pattern resembled that produced by
mutants in the gene coding the glucosyltransferase that adds
the outermost Glc to the glycan in Dol-PP–G3M9 biosynthesis
(alg10mutants, Fig. 1) (16). Thus, the NLO pattern produced
bygls1-Hmutants in which a large amount ofM9 glycans was
produced is most probably due to a partial defect in the biosyn-
thesis of the LLO that is processed to G1M9 and M9 by GII
upon transfer to proteins. The remaining G3M9 in glycopro-
teins of gls1-H mutants could be explained by the small
amount of G3M9 LLO in this strain that is transferred to pro-
teins but could not be trimmed as it lacks a functional GI. As
expected, gls1-S mutants only displayed G3M9 LLO struc-
tures, the same asWT cells (Fig. 4C).
Mutation in alg10 gene significantly improves the growth
andmorphological defects of S. pombe GImutants
As the LLOpattern produced bygls1-Hmutants resembled
that present inalg10mutants (16), we compared the sequence
of the alg10 gene ingls1-S andgls1-H strains.We obtained
the whole alg10 gene (including introns and 5 and 3 UTR
regions) by PCR from genomic DNA extracted from WT and
both gls1 mutants using a high-fidelity polymerase. Upon
DNA sequencing, we found an insertion of a thymidine at posi-
tion 477 from the start codon in the alg10 gene obtained from
gls1-H DNA. The mutation was absent in alg10 sequences
obtained fromWT and gls1-S DNAs, which were identical to
the annotated sequence in the PomBase database (Fig. 5A) (17,
18). The insertion in mutant gls1-H produces a sequence
frameshift that results in a premature stop codon. A 183-amino
acid protein was then probably synthesized instead of the 445-
amino acid normal one. This confirms that in the mutant with
the healthier phenotype an additional mutation in gene alg10
had arisen spontaneously. As in mutant gls1-H, a very small
amount ofG3M9LLO is still formed (Fig. 4B), and themutation
probably does not completely abolish the alg10 gene product
activity.
To confirm that a deletion of alg10 gene can indeed
improve most of the growth defects of gls1-S mutants, we
constructed a S. pombegls1/alg10 doublemutant strain by a
genetic cross using as parental strains gls1-S (gls1-S strain
in which the mating type had been converted to h to allow
mating) (Table 1) and a strain in which the gene alg10 had
been deleted (alg10). We verified the genotype of the double
mutant by antibiotic resistance and by PCR (Fig. S1). We then
Figure 3. NLOs were synthesized in vivo by S. pombemutantsWT (A), gls1-S (B), and gls1-H (C). S. pombe exponentially growing cultures were washed and
labeled with 5mM [14C]Glc for 15min in the presence of 5 mM DTT and 3.5 mM kifunensine (an ER -mannosidase inhibitor). D,gls1-H cells were additionally
labeled in thepresenceof theglucosidase inhibitors CST andNM-DNJ. EndoH–sensitiveN-glycanswerepurified, runonpaper chromatography in 1-propanol/
nitromethane/water (5:2:4), eluted, and further resolved by HPLC. Positions of standards are indicated by arrows.
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compared the growth rate in richmediumof the doublemutant
with that of WT and single alg10, gls1-S, and gls1-H
mutants. The gls1/alg10 double mutant showed a growth
curve very similar to that of the single mutant gls1-H, with all
its growing parameters significantly improved compared with
those of gls1-S strain: a shorter lag time, a duplication time at
the mid-exponential phase more than twice faster than that of
the gls1-S strain, and a maximum OD at 600 nm that was
about 65% that of theWT strain (Fig. 5B, Fig. S2, and Table S1).
However, theWT or alg10mutant strain growth parameters
were not completely restored.
The aberrant morphology observed ingls1-S yeast mutants
was also restored to a much normal one when an additional
mutation in its alg10 gene was introduced (Fig. S3). Although
gls1-S strain cultures had mostly small-rounded cells, the
gls1-H and gls1/alg10mutants had rod-shaped cells simi-
lar toWT andalg10 cells, although still a bit shorter. To quan-
tify the improvement, we calculated the average cell length of
the gls1/alg10 double mutant in liquid culture and com-
pared it with those ofWT, alg10, and gls1 strains. Length
measurements of gls1/alg10,WT, alg10, and gls1 cells
indicated that the double mutant significantly increased its
length with respect to the gls1-S ones and that there were
no statistically significant differences between gls1-H and
gls1/alg10 cells (Fig. 5C). Taken together, these results
indicate that the gls1 defects were suppressed or at least
significantly improved by a simultaneous mutation in the
alg10 gene.
Asgls1-H arose spontaneously as a suppressor mutant dur-
ing meiosis and spore formation, we wondered whether sup-
pression was also a survival strategy during vegetative growth.
We grewgls1-Smutants up to stationary phase and initiated a
new culture at least five times. Comparison of the growth rate of
the resulting culture with that of gls1-H mutants suggested
that defects in the “true” gls1mutants are so severe that cells
tend to revert by suppression after several passages, as reverted
gls1-S (gls1-S-R) and gls1-H cells showed the same growth
rates (Fig. 5D).
Lack of G3M9NLO deglucosylation and not the absence of GI
is themain cause of the sick phenotype ofgls1 cells
Results reported above indicate that mutation of GI-encod-
ing gene produces a very sick phenotype, that the mutant is
unable to process G3M9 NLO, and that its growth defects can
be at least partially suppressed by a simultaneous mutation in
the alg10 gene. A mutation in the alg10 gene is expected to
result in the accumulation of G2M9 LLO in the ER membrane,
which eventually may be transferred to proteins by OST,
although maybe less efficiently than G3M9. Therefore, we
determined the LLO and the NLO patterns produced in vivo by
gls1/alg10 S. pombe double mutants (Fig. 6). The LLO pat-
tern showed that the main LLO produced in vivo was G2M9,
plus a small amount of G1M9. This LLO pattern was similar to
that produced by thegls1-H strain except for the total absence
of G3M9 in the double mutant. This result was consistent with
a complete absence of alg10p activity (compare Fig. 6A with
4C). Accordingly, noG3M9NLOwas observed ingls1/alg10
mutants, even though these cells lack GI (Fig. 6B). Moreover,
almost all NLOs were M9, suggesting that GII had trimmed
efficiently the middle and innermost glucoses of the transferred
G2M9 glycans. The largest NLO detected was G2M9 upon addi-
tion of glucosidase inhibitors (CST andNM-DNJ), thus indicating
Figure 4. Dol-PP-linked oligosaccharide (LLO) in vivo synthesized by
S. pombemutants.WT (A), gls1-H (B), and gls1-H (C) exponentially grow-
ing mutant cells were labeled with [14C]Glc for 15 min in the presence of
cycloheximide and puromycin. Glycans obtained by mild acid hydrolysis
were analyzedbypaper chromatography in 1-propanol/nitromethane/water
(5:2:4), eluted and further solved by HPLC. Positions of standards are indi-
cated by arrows.
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that such a structure was the one transferred in gls1/alg10
mutants (Fig. 6C).
Our results confirm that cells with a mutation in alg10
genes transfer glycans with the structure G2M9 to proteins and
that such defect can suppress the sick phenotype observed in
mutants lacking GI. Results also indicate that the presence of
triglucosylated glycans in proteins is probably the cause of the
severe growth defects observed in the “true” gls1-S mutant
cells. The fact that the phenotype of the gls1/alg10 double
mutant is so similar to that ofgls1-H strain would suggest that
the amount of G3M9 produced by the last strain is too small to
produce the toxicity observed in gls1-S strain. Our results do
not rule out, however, the possibility that GI plays an additional
role in the ER, as bypassing its necessity for further glycan pro-
cessing by simultaneously mutating the alg10 gene did not fully
restore theWT phenotype.
Figure 5. Mutation in alg10 gene suppresses the growth defects of gls1-S mutants. A, sequence profile of alg10 gene in gls1-S and gls1-H
mutants. The complete alg10 gene was obtained by PCR from genomic DNA purified from WT and both gls1 mutants. The products were sequenced
and comparedwith the annotated sequence in PomBase. B, growth profile of S. pombemutant strains in liquid-rich YESmedia. Triplicate cultures of each
plotted mutant were started at A600 nm  0.2 and grown at 28 °C for 5 days. Aliquots were taken every 4 h and plotted. Data were analyzed using R
software. C, morphology of WT, alg10, and gls1 mutants. Cells were grown in liquid media to an A600 nm  1 and photographed with a bright field
microscope. Cell lengths (at least 180 for each culture) weremeasured using ImageJ software. Statistical analyses were done using one-way ANOVA and
Bonferroni’s multiple comparison tests. Different letters (a–c) indicate statistically significant (p	 0.0001) differences.D, reversion of the growth defect
in gls1-S mutants after several passages. gls1-S and gls1-H mutants were grown in liquid YES media until saturation, diluted 1:100 in fresh media,
and grown again several times. Finally 5l of 10-fold serial dilutions of the cultures were plated in solid-richmedia and grown for 72 h at 28 °C.gls1-S-R
states for the reverted gls1-S strain after several passages.
Table 1
S. pombe strains used in this work
Strain (nickname) Genotype Origin
ADm (WT) h, ade6-M210, leu1-32, ura4-D18 Our stock (31)
gls1::KanMX/ diploid h/h, ade6-M210/ade6-M216, leu1-32/leu1-32, ura4-D18/ura4-D18, gls1::KanMX/ Bioneer
gls1::NatMX/ diploid h/h, ade6-M210/ade6-M216, leu1-32/leu1-32, ura4-D18/ura4-D18, gls1::NatMX/ This work
GI-10A (gls1-S) h, leu1-32, ade6-M216, ura4-D18, gls1::NatMX4 This work
GI-10D (gls1-H) h, leu1-32, ade6-M216, ura4-D18, gls1::NatMX4 This work
GI-210m1A (gls1-S) h, leu1-32, ade6-M210, ura4-D18, gls1::NatMX4 This work
SPAC56F8.06c (alg10) h, leu1-32, ade6-M216 ,ura4-D18, alg10::KanMX4 Bioneer
GIA10–18 (gls1/alg10) h, leu1-32, ade6-M210, ura4-D18, gls1::NatMX4, alg10::KanMX4 This work
Sp61II (gls2) h, leu1-32, ade6-M210, ura4-D18, ade1, gls2::ura4 Our stock (43)
SpAC227.11c (yos9) h, leu1-32, ade6-M210, ura4-D18, yos9::KanMX6 Bioneer
Sp61A (alg6) h, leu1-32, ade1, ade6-M210, ura4-D18, alg6::ura4 Our stock (45)
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Sick phenotype ofgls1-Smutants is not due to the
impossibility of their glycoproteins to interact with CNX or
enter quality control cycles in the ER
Cellular effects produced in gls1-Smutants could be due to
the lack of interaction of their triglucosylated glycoproteins
with CNX. To test whether the absence of lectin–glycoprotein
interactions could be the cause of the sick phenotype observed
in gls1-S mutants, we compared the growth rates of WT,
gls1-S, and gls2 mutant cells. As the last ones lack the GII
catalytic subunit, they are unable to deglucosylate G2M9 gly-
cans and, the same as in gls1-S cells, their glycoproteins can-
not interact with CNX. However, gls2 S. pombe mutants
grew normally when compared withWT cells and much better
than gls1-S mutants (Fig. 7). These results indicate that the
absence of CNX–glycoprotein interaction does not affect
growth rate and therefore cannot be the cause of the sick phe-
notype observed in gls1-Smutants.
S. pombe cells that lack key components of the ERAD
machinery grow normally
OS9 (Yos9p in yeasts), a key component of the ERAD
machinery, is a lectin that upon recognition of ER-demannosy-
lated glycans drives irreparablymisfolded glycoproteins to pro-
teasomal degradation (Fig. 1B). Mutants lacking Yos9p sub-
stantially delay misfolded glycoprotein degradation (19, 20).
We hypothesized that if irreversibly misfolded glycoproteins
bearing three Glc moieties in gls1-S cells were not demanno-
sylated in the ER or were not recognized by Yos9p, then
S. pombe yos9 mutants would present growth defects similar
to those in gls1-S cells. Comparison of yeast WT, yos9, and
gls1-S mutant cell growth rates indicated that a limitation in
the degradation of misfolded glycoproteins did not result in
noticeable growth defects (Fig. 7).
OST transfer activity is not significantly inhibited in cells
unable to deglucosylate G3M9NLOs
Our results point to the accumulation of triglucosylated
NLOs to be responsible for the severe defects observed in
gls1-S yeast cells. Such accumulation could inhibit the OST
complex, as those glycans are the product of its transfer reac-
tion, thus reducing the glycan-transfer rate. Therefore, this
would result in a protein hypoglycosylation similar to that
observed when the N-glycosylation inhibitor tunicamycin is
added to cells (21). To test this hypothesis, we analyzedwhether
protein hypoglycosylation occurred in S. pombegls1mutants.
We tested the glycosylation status of CNX, a resident ER glyco-
protein with a single glycosylation site, that at nearly stationary
phase normally presents soluble and membrane-bound iso-
forms (22). Upon treatment of cell extracts with EndoH, mem-
brane CNX isoform of all strains tested (WT, gls1-S, gls1-H,
gls1/alg10, andalg10) showed an
2-kDa faster migrating
band (Fig. 8A). Only alg10, gls1-H, and gls1/alg10
mutants showed a hypoglycosylation pattern, with a double
band corresponding to glycosylated and nonglycosylated CNX
Figure 6. NLOs and LLOs produced by S. pombe gls1/alg10 double
mutant. Cells were labeled in vivo with [14C]Glc for 15 min. NLOs and LLOs
were purified and analyzed by paper chromatography in 1-propanol/nitro-
methane/water (5:2:4), eluted,and further resolvedbyHPLC.Positionsof stan-
dards are indicated by arrows.
Figure 7. Comparison of the growth phenotype of gls1-S cells with
those of S. pombe mutants whose glycoproteins are unable to interact
with CNX or display a defective ERAD pathway. WT and the indicated
mutant cells were grown up to A600 nm 1, and drops (5 l) of 10-fold dilu-
tions were plated on YES. Plates were incubated for 72 h at 28 °C.
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in the absence of Endo H treatment. No double band was
observed in thegls1-Smutants in the absence of Endo H, thus
indicating that CNXwas originally fully glycosylated ingls1-S
mutants and that the OST ability to transfer pre-assembled
glycans to proteins was not affected in that strain (Fig. 8A).
The possibility remained, however, that other glycoproteins
different from CNX had affected their glycosylation degree by
OST in the gls1-S mutant. We reasoned that if this were the
case, OST overexpression in that mutant would relieve the
hypoglycosylation that may occur in any ER glycoprotein.
Mammalian and yeast OST are multisubunit complexes whose
catalytic subunit is STT3 (23).We expressed Leishmaniamajor
STT3D, a single-subunit OST of broad-range specificity (24).
This OST would not be inhibited by the accumulation of trig-
lucosylated proteins as its natural substrate is M7, the main
glycan transferred in those parasites (25). The protein was
expressed correctly in the ER, as its expression was enriched in
microsomes when compared with total-cell extracts (Fig. 8B).
Moreover, L. major STT3D was able to correct CNX hypogly-
cosylation observed in an alg6mutant (Alg6p is the glycosyl-
transferase responsible of the addition of the first Glc in G3M9
LLO synthesis, and its absence results in M9 transfer to pro-
teins and in a severe protein hypoglycosylation) (Fig. 8C) (26).
However, no changes in the growth defects of gls1-S were
observed upon L. major STT3D expression in this strain (Fig.
8D). This suggests that an inhibition of the N-glycosylation
reaction is not the cause of the phenotypic defects observed in
the gls1-Smutants.
Persistence of three Glc units in the transferred glycan neither
precludes glycoprotein extension in the Golgi nor affects
S. pombe cell-wall monosaccharide composition
We wondered whether the continued presence of Glc resi-
dues in the armAof the glycan could preclude glycan extension
with Man and Gal residues in the Golgi, thus reducing the size
of protein-linked galactomannans at the cell surface or some-
how affecting cell-wall synthesis. We compared the size of
NLOs produced by mutant gls1-S that conserved triglucosy-
lated glycoproteinswith that ofgls2mutant, which displayed
instead diglucosylated glycoproteins. We labeled cells with
[14C]Glc for 45 min in the absence of DTT, chased them with
Glc for 150 min, and isolated NLOs from total-cell glycopro-
Figure8.OSTproteinglycosylationactivity is not affected ingls1-Smutants.A,glycosylation status of CNX in S. pombegls1mutants. Cell extractswere
prepared from S. pombe cultures grownup toA600 nm 1, treated or notwith EndoH, solved by SDS-PAGE 12%, and analyzed byWestern blotting using rabbit
anti CNX serum 1:10,000 as primary antibody and anti-rabbit HRP 1:30,000 as secondary antibody. B, expression of L. major STT3D in S. pombemutants.WT or
gls1-S mutants were transformed with HA-epitope–tagged L. major STT3D. Total-cell extracts and ER-enriched fractions were obtained, and 50 g of each
submitted to a 12% SDS-PAGE followed by immunoblot using rat anti-HA 1:5000 (Roche Applied Science) followed by anti-rat conjugated to HRP 1:5000
(Sigma). C, reversion of CNX hypoglycosylation in alg6 mutants expressing L. major STT3D. Cell extracts were prepared from the indicated S. pombe strains
and analyzed as in A. D, L. major STT3D overexpression does not suppressgls1-S growth defect.WT orgls1-Smutants transformed with L. major STT3 were
grown in EMMmedium supplementedwith adenine and uracil up to A600 nm 1. Drops (5l) of 10-fold dilutionswere plated on solidMMAU an incubated for
72 h at 28 °C.
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teins. As expected, after 45 min labeling NLOs obtained from
gls2 mutants were mainly G2M9 and those obtained from
gls1-S were G3M9, consistent with the absence of GII and GI
activities in the ER, respectively. After 150 min chase, both
mutants were able to extend their NLOs in the secretory path-
way, and almost no differences were observed between GI- and
GII-lacking mutant patterns (Fig. 9). Moreover, the cell wall
polysaccharide composition of both mutants was indistin-
guishable from each other (Fig. S4) and from that of WT cells
(27) as they produced mainly Glc, but also Man and Gal. As
growth rate differences between both strains are evident (Fig.
7), these results indicate that the impossibility of trimming Glc
units in the ER did not preclude NLO elongation and that it is
not the main cause of the growth impairment of gls1-S cells.
Cells lacking GI exhibit a thick cell wall and lack a visible
underlying ER
It has been reported that S. cerevisiae mutants in the OST
catalytic subunit STT3 exhibit a diffused cell wall with loss
of the outer mannoprotein layer (28). Transmission electron
microscopy (TEM)ofWT,gls1-S, andgls2mutants showed
that the cell wall of gls1-S is thicker than the others, has a
feathered appearance, and lacks the characteristic three-lay-
ered structure typical ofWT cells (Fig. 10, A–C) (29). Quantifi-
cation of the electron-density profiles (Fig. 10,D–F) was shown
to be relatively homogeneous in thegls1-Smutant. This result
correlates with the diffuse appearance of its cell wall. Interest-
ingly, this profile appears to be specific for cells lacking GI and
bearing triglucosylated glycoproteins, as cells lacking GII and
thus bearing diglucosylated glycoproteins display a cell wall
identical to that ofWT cells.Moreover, TEM comparison of ER
structures localized below the plasma membrane of WT,
gls1-S, and gls2mutants showed a defined ER structure in
theWT and gls2 strains that was absent in gls1-Smutants,
thus suggesting that the ER structure may be altered or dis-
torted in the last strain or that the contact sites between the ER
and the plasma membrane are lost (Fig. 10, A–C).
Continued presence of triglucosylated glycoproteins results in
cell death
To understand the severe growth defect in cells unable to
remove the glucoses from NLOs, we wondered whether there
was a loss of viability at a particular phase in the fission yeast
growth curve. Dead cells or cells with a reduced metabolism
cannot efficiently exclude the fluorescent dye phloxine B (Fig.
S5A). We thus analyzed the ability of individual S. pombe cells
ofWT, gls1-S, gls1-H, gls1/alg10, and alg10 cultures to
exclude phloxine B by flow cytometry (Fig. S5B), and we calcu-
lated the proportion of cells excluding it at all phases of the
growth curve (Fig. 11A). The proportion of live and metaboli-
cally active cells ingls1-S cultures wasmarkedly reduced at all
growth phases when compared with that in WT ones (p 	
0.001). gls1-S cell viability reached its maximum at the expo-
nential phase, but the value did not exceed 30% that of WT
cells. The proportion of live cells in gls1-S cultures dramat-
ically dropped in the stationary phase. On the contrary,
Figure 9. Glycan extension of glycoproteins in S. pombemutants lacking either GI or GII. Cultures of S. pombemutantsgls2 (A and C) orgls1-S (B and
D) were labeled for 45 min with 5 mM Glc in the presence of 300 Ci/ml [14C]Glc (C and D) and chased for 150 min with 100 mM Glc. NLOs were purified and
analyzed by paper chromatography in 1-propanol/nitromethane/water (5:2:4), eluted, and further solved by HPLC. Positions of standards are indicated by
arrows.
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gls1-H and gls1/alg10 mutants showed a proportion of
metabolically active cells that was significantly higher than
the gls1-S ones (p 	 0.05) at all stages of the growth curve.
They were 45–60% (gls1-H) and 30–50% (gls1/alg10)
that of WT cell values (Fig. 11A). Results obtained using the
exclusion of a vital dye as an indication of vital activity were
compared with the ability to generate new colonies (% CFU)
of each strain’s cells (Fig. 11B). The CFU percentage values
were reduced at all stages in the gls1-S strain. The decrease
was especially severe at the stationary phase. Conversely, the
gls1-H and gls1/alg10 mutant CFU percentage values
were quite similar to those of WT cells, and this fact was
consistent with the observed suppressed phenotype of the
mutants.
Expression of human endomannosidase relieves thegls1-S
mutant sick phenotype
Mammalian cells display an endomannosidase in the Golgi
whose expression levels are enhanced in MOGS-CDG patients
(13). The enzyme cleaves the bond between Man f and Man g
(Fig. 1A) provided either one, two, or threeGlc units are present
in the glycan (30). In addition to protein-linked M8, it yields
Glc1–3Man depending on the substrate hydrolyzed. Although
about 80% of glycans in MOGS-CDG patients are then nor-
mally processed in the Golgi, they still present a very sick
pathology. As S. pombe lacks any endomannosidase activity, we
expressed human endomannosidase (hEM) as a GFP fusion
(schematized in Fig. 12A) in S. pombe gls1-S and gls2
mutants. The GFP-hEM clone was active in S. pombe as micro-
somes obtained from the transformed gls2 strain were able
to release a disaccharide fromglucose-labeledG1M9 (Fig. 12B).
The rationale for the use of cells lacking GII to test for endo-
mannosidase activity was to prevent removal of the single Glc
from such substrate, in addition to the disaccharide Glc-Man,
a fact that would obscure results (Fig. 1A). The active hEM
expressed in both gls1-S and gls2mutants presented a typ-
ical Golgi pattern localization for fission yeasts when observed
by confocal microscopy (Fig. 12C). Those GFP-fluorescent
membrane vesicle-like structures distributedwithin the cell did
not correspond to endocytic or degradation vesicles as they did
not co-localize with the endocytic pathway-specific dye FM464
(Fig. 12C). We then compared the growth rate of gls1-S
mutants expressing hEM with those of cells transformed with
WT gls1 or with an empty vector. Results obtained showed
that expression of hEM in the Golgi of gls1-Smutants signif-
icantly relieved the sick phenotype but not as well as expression
of WT GI (Fig. 12D).
Discussion
In an attempt to understand the molecular basis of the
pathology observed in individuals withmutations in the GI-en-
coding gene and thus bearing MOGS-CDG (also known as
CDG-IIb), we reproduced in the fission yeast S. pombe the
genetic defect of the disease.We obtained twomutants:gls1-S
mutant had a severe growth defect and an aberrant morphol-
ogy, andgls1-Hmutant had an almost normal phenotype (Fig.
2).We characterized theNLOsof both strains, and surprisingly,
in the healthier gls1-H cells most of the NLOs were fully
trimmed M9 species (Fig. 3). We speculated that these NLOs
could have been formed uponGII deglucosylation of an incom-
plete glycan transferred to proteins. Analysis of LLOs present in
the gls1-H strain showed that G2M9 was the main species
(Fig. 4B). This indicated that the LLOhad not reached the com-
plete G3M9 structure, so we speculated that a suppressing
mutation had arisen in the enzyme Alg10p responsible for the
addition of the outermost glucose to the LLO (Fig. 1). The
sequence of alg10 gene in gls1-H mutants showed indeed an
insertion that produced a frameshift in the coding sequence
Figure 10. gls1-S mutants exhibit changes in the cell wall and in the underlying ER structures. A–C, transmission electron microscopy images of
S. pombeWT (A),gls1-S (B), andgls2 (C)mutants. Cellsweregrown toA600 nm1 (0.2) and fixedwith2.5%glutaraldehyde in0.1MPBS supplementedwith
ruthenium red. The cellwall (CW) is indicatedwith abracket and its underlying ERwith anarrowhead. Thearrows inA–C correspond to sections used tomeasure
TEMsignal intensities (bar,0.1m).D–F, representative intensityprofilesof aWT (D),gls1-S (E), andgls2 (F) S. pombe cellwall TEM images.Nine cells for each
genotype were analyzed, and three cross-section intensity profiles per cell were plotted, showing an identical behavior. D–F, displayed are the characteristic
profiles obtained from sections indicated by the arrows in A–C, respectively. A.U., arbitrary units.
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(Fig. 5A). The growth and morphological defects observed in
gls1-S mutants were relieved in the double knockout strain
gls1/alg10 (Fig. 5, B and C, and Table S1). Taken together,
our results indicate that the slow growth and aberrant mor-
phology observed in the nonsuppressed gls1-S mutants were
due to lack of ER G3M9 NLO deglucosylation. This metabolic
defect is, apparently, extremely deleterious for cells as shownby
the difficulty of maintaining an unsuppressed gls1-S yeast
strain: after several rounds of culture replication, the strain
tended to suppress the growth defect and started growing as the
healthier gls1-H (Fig. 5D).
Cellular effects of mutations in GI could be in the ER and/or
Golgi and/or cell surface. Our results indicate that the pheno-
typic defects ingls1-Smutants are not likely due to a hindered
entrance of glycoproteins into the ER quality control of a gly-
coprotein-folding mechanism as yeast mutants lacking GII
activity (gls2 mutants) presented a normal growth rate,
although they accumulated protein-linked G2M9 structures
also unable to enter into such cycles (Fig. 7) (31). A hypothetical
impairment of misfolded triglucosylated glycoproteins to be
recognized by the ERAD machinery does not seem to be the
problem in gls1-S mutants either, as lack of the OS9 lectin
(yos9mutants), which is a central player in the ERAD process
as it recognizes demannosylated misfolded glycoproteins and
drives them to proteasomal degradation, did not result in rele-
vant growth defects. It may be speculated that increased
amounts of triglucosylated glycoproteins in the ERwould result
in a reaction product inhibition of the OST, thus leading to a
severe glycoprotein hypoglycosylation. This appeared not to be
the case either as CNX, an ER resident glycoprotein with a
single glycosylation site, did not show detectable amounts of
hypoglycosylation in gls1-Smutant cells (Fig. 8A). The possi-
bility existed, however, that hypoglycosylation of other pro-
tein(s)may be responsible for the observed phenotypes. Expres-
sion in the ER of alg6 S. pombe mutants of L. major STT3, a
subunit with a broad range of substrate specificity that was able
to replace the whole OST complex in S. cerevisiae (24, 32), was
able to revert the hypoglycosylation produced in such a strain.
However, its expression did not result in a reversion of the
defects in the gls1-S mutants caused by accumulation of
G3M9 NLOs (Fig. 8D), indicating that either there is no OST
reaction product inhibition when G3M9 NLOs are not
trimmed or that it is not severe enough to result in the observed
toxicity.
We next explored the possibility that the presence of three
Glc units could prevent the Golgi extension of protein-linked
glycans by addition ofMan andGal. A size comparison ofNLOs
produced by mutant gls1-S with those of gls2 mutant
showed that both strains were capable of extending their pro-
tein-linked glycans (Fig. 9) and had normal cell wall monosac-
charide compositions (Fig. S4), even though they have very dif-
ferent growth and morphological phenotypes (Fig. 7). As we
evaluated the bulk of cell wall glycoproteins, we cannot exclude
the possibility that a particular glycoprotein displaying an
essential functionality could be affected in gls1-S mutants by
an impaired glycan elongation. Studies on the morphology of
WT, gls1-S, and gls2 cells by TEM showed an altered cell
wall ultrastructure only ingls1-S cells, which lacked the three-
layered structure present in WT and gls2 cells (Fig. 10).
Interestingly, this phenotype resembles that of S. cerevisiae
cells bearing mutations in the catalytic subunit of the OST,
which exhibit a diffused cell wall with loss of the outer man-
noprotein layer present in WT cells (28). The S. pombe ER
structure below the plasma membrane was clearly observed
inWT andgls2 cells by TEM. However, no such structures
were ever observed in gls1-Smutants. The clear differences
observed in ER structures of the strains make attractive the
possibility that accumulation of triglucosylated glycopro-
teins in cells lacking GI somehow alters the secretory path-
way subcellular structure. This hypothesis is currently under
investigation.
Figure 11. Viability of S. pombe mutants at different phases of the
growth curve. A, percentage of cells able to exclude the vital dye phloxine B.
The indicated cell strains were grown in rich media, and aliquots were taken
(triplicates for each growth phase) and incubated with the dye phloxine B.
Fluorescence of 10,000 cells of each sample was analyzed by flow cytometry.
Each bar represents the percentage of fluorescent cells. Mean averages that
are significantly different from each other (p 	 0.0001) are indicated with
different letters and those that are not (p 0.05) are indicated with the same
letter. B, percentage of S. pombe mutant cells able to form a colony at the
different growth phases. Cells were grown in YES, and aliquots (triplicates)
were taken at the different growth phases, diluted, and plated in YEA. After at
least 5 days at 28 °C, colonies were counted. Each bar represents the percent-
age of arisen colonies considering 100% the calculated theoretical number of
cells plated (A600 nm 1 was considered to contain 2.2 10
7 cells/ml). Aster-
isks indicate a significant difference (p	 0.0001) ofgls1-Swith respect to all
other strains.
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Previous reports showed that Caenorhabditis elegans
mutants lackingGI did not display any visiblemorphological or
behavioral phenotypes, but life span was greatly reduced (33).
We thus investigated whether there was a loss of viability in a
particular phase of the fission yeast cell growth curve. With
both parameters analyzed, the proportion of cells that exclude
the vital fluorescent dye phloxine B and the proportion of cells
able to form colony units showed a drastic reduction of viability
Figure 12. Expressed Golgi human endomannosidase is functional in S. pombe and partially rescues the growth defect of gls1-S mutants. A,
schematic representation of the hEM fused to green fluorescent protein (GFP-hEM). TMD, transmembrane domain. B, endomannosidase activity inmicrosomal
fractions ofgls2 S. pombemutants. Release of [14C]Glc-Man from 2000 cpmof [14C-Glc]G1M9wasmeasured using 100g ofmicrosomal fractions obtained
from gls2 S. pombemutants expressing or not GFP-hEM for 30 min at 37 °C. The reaction was stopped with methanol, and released Glc-Man disaccharides
were separated from the substrate on paper chromatography using 2-propanol/acetic acid/H2O (25:4:9). C,GFP-hEM shows a typical Golgi distribution, and it
is excluded from endocytic and vacuolar compartments. Confocal images ofgls1-S andgls2 expressing GFP-hEM that were stainedwith FM4-64 dyewere
obtained by confocal microscopy using 488 nm argon and 543 nmHe-Ne lasers, respectively. Scale bar, 5m.D, relief of the growth defect ofgls1-Smutants
expressing GFP-hEM. gls1-S strains transformed either with empty vector, GFP-hEM, or gls1 were grown up to A600 nm  1, and drops (5 l) of 10-fold
dilutions were plated on minimal medium lacking leucine. Growth of different strains was compared after a 6-day incubation at 28 °C.
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at all phases of the growing curve, although the effects were
more severe at the early stationary phase (Fig. 11).
Mammalian cells have a Golgi endomannosidase that
removes G3M from protein-linked G3M9 (Fig. 1) (34). Expres-
sion of the enzyme is enhanced in fibroblasts of patients dis-
playing the MOGS-CDG syndrome thus allowing synthesis of
complex type NLOs in the Golgi, more than 80% of which dis-
play structures similar to those present in healthy cells (13).
Nevertheless, affected individuals still display extremely severe
phenotypes. It is unknown whether these are caused by the

16%of remaining noncanonicalNLOs or, alternatively, by the
extended occurrence of triglucosylated glycans. Expression of a
functional Golgi hEM in the Golgi of gls1-S significantly
relieved the sick phenotype of the cells, although not as well as
expressing GI (Fig. 12). This indicates that the toxic effect
exerted by triglucosylated glycoproteins takes place in theGolgi
(or ahead in the secretory pathway), that endomannosidase
expression has not completely removed the harmful structures,
or alternatively, that the extended occurrence of triglucosylated
glycoproteins in the ER, theGolgi, and beyond results in growth
defects.
In conclusion, we demonstrated that the inability to deglu-
cosylate protein-linked G3M9 glycans in the ER is extremely
toxic to the fission yeast. Although we were unable to exactly
pinpoint either the cause or the subcellular site of toxicity, we
propose that the persistence of those structures may be, at least




Yeast extract and Malt extract were from Britania (Buenos
Aires, Argentina). Bactopeptone and yeast nitrogen base (YNB)
were from Difco (Detroit, MI). Endo H, protease inhibitors,
dithiothreitol (DTT), amino acids, and supplements for culture
media were from Sigma. [14C]Glc (301 Ci/mol) was from
PerkinElmer Life Sciences. NM-DNJ was from Toronto Bio-
chemicals. Enzymes used for general DNA procedures were
from New England Biolabs (Ipswich, MA), and LR clonase was
from Invitrogen. Geneticin (G418)was from InVivoGen (Carls-
bad, CA), and nourseothricin was from WERNER BioAgents
(Jena, Germany).
Strains andmedia
Escherichia coliDH5 and JA226 were used for cloning pur-
poses and DB3.1 to amplify Gateway plasmids bearing the ccdB
gene. Bacteria were grown at 37 °C in Luria broth medium (LB:
0.5% NaCl, 1% tryptone, and 0.5% yeast extract), supplemented
with 200 g/ml ampicillin or 50 g/ml kanamycin as needed.
S. pombe strains were grown at 28 °C in low adenine-richmedia
YE (0.5% yeast extract, 3% glucose) when testing for ade6 gen-
otype or in YES medium (YE medium supplemented with 75
mg/liter adenine). S. pombe were selected in EMM minimal
medium (35, 36) supplemented with adenine 75 mg/liter, leu-
cine 250 mg/liter, or uracil 75 mg/liter as required. Geneticin
was added to YESmedia at 200g/ml for kanMXmarker selec-
tion, and nourseothricin was added to YES media at 100 g/ml
for NatMX marker selection. When double selection for
geneticin and auxotrophic markers was needed, NH4Cl was
replaced by 0.37% monosodium L-glutamate as the nitrogen
source in EMM. Malt extract medium (3% Bacto Malt Extract,
pH 5.5, supplemented with adenine, uracil, and leucine) was
used for matings. The S. pombe strains used in this work are
summarized in Table 1.
DNA and cloning procedures
General DNA procedures were as described previously (37).
Yeast DNA extraction was performed as described in Ref. 38.
The alg10 gene in S. pombe WT, gls1-H, and gls1-S
strains was amplified in two parts using genomic DNA of each
strain as a template and the primer pairs alg10–5NC (5-CC-
AAACTTCCTGCCAACAAC-3)/alg10rev (5-CAATCCCC-
ACTTAGCTGAAG-3) and alg10fw (5-CTGGCTTGTAGG-
CGTAATTG-3tj;1)/alg10–3NC (5-GGTGCTCGTT-
GATTTTTGGT-3) in a high-fidelity PCR using KOD
(Merck). Both PCR products obtained from each mutant were
purified by QIAquick gel extraction kit (Qiagen) and sequenced.
The gateway pDONR201 plasmid containing clone 28/H08
(S. pombe gls1 gene, which was obtained from RIKEN DNA
Bank (39))was transferred to the pREP41-ccdb2Gateway-com-
patible S. pombe destination expression vector (kindly provided
by Dr. M. Yoshida, Chemical Genetics Laboratory, RIKEN
DNA Bank, Japan) by the LR recombination reaction (Invitro-
gen) as indicated by the manufacturer. Recombinant expres-
sion plasmid was amplified and recovered from JA226 E. coli
strain. S. pombe competent gls1-S cells were then electropo-
rated with the pREP41-GI episomal-replicating constructs and
selected in EMM supplemented with adenine and uracil.
L. major STT3D was amplified from plasmid pRS425-
STT3D (kindly provided by Dr. Markus Aebi, ETH, Zurich,
Switzerland) (24) in-frame with a sequence coding the hemag-
glutinin (HA) epitope tag using the following primers that pro-
vide at both ends the attB sites for Gateway recombination:
attB1-STT3D fw (5-GGGGACAAGTTTGTACAAAAAAG-
CAGGCTGGATGGGCAAGCGGAAGGG-3) and attB2
stop STT3D rev (5-GGGGACCACTTTGTACAAGAAAGC-
TGGGTtcaAGCGTAATCTGGAACGTC-3). The 2600-bp
fragmentwas introduced in pDONR-201ccdB vector by recom-
bination using BP clonase (Invitrogen) and the plasmids recov-
ered fromDH5E. coli strain. Positive cloneswere identified by
colony PCR using primers attb-STT3fw and pDONR201a (5-
CATCAGAGATTTTGAGACAC-3) and sequenced. The
insert was then transferred to a pREP1-ccdB (Riken) (39) desti-
nation vector using LR clonase as described above. The result-
ing expression vector pREP1-STT3D-HA was sequenced and
electroporated intoWT and gls1-S yeast cells. Transformants
were selected in EMM lacking leucine.
Human Golgi endomannosidase fused to GFP was amplified
with KOD polymerase from plasmid pSV-GFP-hEM (34) using
primers pREP3X-XhoI-fEGFP (5-TTCTCACTTTCTGACT-
TATAGTCGCTTTGTTAAATGGCCTCGAGATGGTGAG-




40 bp of flanking homology to S. pombe expression
vector pREP3X. The insert was cloned by gap repair in S. pombe
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by transforming competentWT cellswith 5g of the insert plus
1g of pREP3X previously opened with SmaI and XhoI restric-
tion enzymes (40, 41). Transformants selected in EMM lacking
leucine were screened by colony PCR to detect the presence of
plasmid pREP3X-GFP-hEM produced by homologous recom-
bination. Total DNA obtained from positive cells was used to
transform E. coli, and plasmids were recovered and sequenced
(41). The same clone was introduced into gls1-S and gls2
S. pombe strains.
Genetic procedures
S. pombe transformations by electroporation—S. pombe elec-
trocompetent cells were prepared by extensively washing expo-
nentially growing cultures twice with 1 volume of sterile water,
twice with 1 M sorbitol, and finally resuspended at a 1:100 of the
initial volume in 1 M sorbitol. Plasmidic supercoiled DNA (0.2
g) or linearDNA (0.5–1g)were electroporated at 1.5 kV, 200
ohm, 25microfaradswith aGene Pulser II (Bio-Rad). Cells were
recovered in 0.5 M sorbitol in YES for 1 h at 28 °C, harvested,
and plated in the appropriate selective media.
Construction of gls1::NatMX haploid strains—The geneti-
cin resistance cassette of the heterozygous gls1::KanMX/
diploid S. pombe strain purchased from Bioneer (Korea) was
exchanged by the nourseotricine resistance cassette according
to Sato et al. (42) as follows: primers MD1 (5-CGGATCC-
CCGGGTTAATTAAGGCG-3) and MD2 (5-GAATTCGA-
GCTCGTTTAAACACTGGATGGCGGCGTTAGTATCG-3)
were used in a PCR using KOD (Merck) to obtain NatMX6
(nourseothricin-resistant marker) flanked by promoter PTEF
and terminator TTEF using plasmid pCR2.1-Nat as a template
(kindly provided by Takashi Toda, London Research Institute,
UK). This DNA fragment was gel-purified and used to trans-
form electrocompetent gls1::KanMX/ diploid S. pombe
mutants. Nourseothricin-resistant gls1::NatMX/ diploid
S. pombe colonies were tested for sensitivity to geneticin, and
homologous recombination was verified by PCR using primers
gls1–5NC B (5-GCTCCAAATGTTTTACG CAG-3) and
ClonNAT rev (5-CGAGACGACCACGAAGC-3). To obtain
haploid gls1::NatMX strains, sporulation was induced by
transformation of the nourseothricin-resistant diploid strain
with plasmid pON177 (Bioneer) according to company instruc-
tions followed by selection of uracil phototrophs. Spore micro-
manipulations were carried out with a Manual Micromanipu-
lator (Singer Instruments Co). gls1::NatMX genotypes of the
spores were determined by antibiotic resistance and also by
colony PCR with the primers ClonNAT fw (5-CTTCGTGGT-
CGTCTCGTAC-3) and gls1–3NCB (5-AAATACGAAACG-
CAGTTCGC-3). gls1-S and gls1-H haploid nourseothricin
mutants were obtained from the dissection of the same tetrad
(Table 1).
Construction of S. pombe double mutants—S. pombe alg10
and yos9 mutants were purchased from Bioneer (Korea).
S. pombe gls2 strain construction was described previously
(43). Double mutants were obtained using standard genetic
techniques for mating, sporulation, tetrad dissection, and anal-
ysis, as described previously (27, 35). Relevant genotypes were
determined by antibiotic resistance or auxotrophic growth in
the appropriatemedia and also by colony PCRwith the primers
described below. To construct GIA10-18 strain, first haploid
gls1-Swas mated with ADm to obtain GI210m-1A. This h
strain was in turn mated with strain alg10 (SPAC56F8.06c),
and the diploids obtainedwere sporulated and tetrads dissected
by micromanipulation. The genotype of the resulting spores
that were both geneticin- and nourseothricin-resistant was
confirmed by PCR using the primer pairs ClonNAT fw/gls1–
3NC B for gls1::NatMX and Spalg10s 5NC (5-CCA-
AACTTCCTGCCAACAAC-3)/KanMXrev2 (5-CGCTAC-
CTTTGCCATGTTTCAG-3) for alg10::KanMX, respec-
tively. Mating types were determined by PCR as described (44).
Analysis of NLO and LLOs synthesized in vivo
S. pombe cultures in exponential growth phase were har-
vested, extensively washed with 1% YNB medium without glu-
cose, and resuspended in 2 volumes (v/w) of the samemedium.
For NLO analysis, 0.5 ml of cells were preincubated with the
mannosidase inhibitor 3.5 mM kifunensine for 30 min and with
5mMDTT for 5min and pulsed for 15min in 5mMGlcwith 300
Ci/ml [14C]Glc at 28 °C.WhenGI andGII inhibitors CST and
NM-DNJwere used, theywere added 60min prior to labeling at
8.5 and 5 mM, respectively. Purification and protease digestion
of glycoproteins and Endo H–sensitive NLO purification were
performed as described previously (10). Glycans were run on
paper chromatography in Whatman 1 papers and 1-propanol/
nitromethane/H2O (5:2:4) as solvent, and peaks were identified
by standards run in parallel. To improve the resolution of the
glycan species, the identified glycans were eluted from the
papers and resolved by HPLC using a TSK-GEL Amide-80 col-
umn (4.6 mm inner diameter  25 cm; Tosoh Bioscience,
Tokyo, Japan) with a mobile phase of H2O/CH3CN in a linear
gradient from 35:65 to 55:45 over 65min and a flow rate of 0.75
ml/min at room temperature as reported (45). For the analysis
of LLO, 1ml of washed cells were pulsed for 15min in 5mMGlc
with 300 Ci/ml [14C]Glc at 28 °C in the presence of 50 g/ml
puromycin and 75 g/ml cycloheximide. Cells were precipi-
tated with 5 ml of methanol, and the pellet was extracted three
times with CHCl3/methanol (3:2). The pellet was then washed
once with methanol and once with water, resuspended in 2 ml
of water and 1 ml of glass beads, vortexed for 10 min, and cen-
trifuged. The resulting pellet was washed four times with water
and then extracted with CH3CN/methanol/water (1:1:0.3). The
extracted material was dried and boiled for 15 min in 1 ml of
0.02 NHCl.Once cold, 3ml ofCHCl3 and 2ml ofmethanolwere
added and centrifuged. The upper phase was recovered, dried,
and analyzed as described for NLO.
Analysis of glycan extension in the secretory pathway and cell
wall composition of GI and GII mutants
S. pombe cultures in exponential growth phase were har-
vested and washed with 1% YNBmedium without glucose, and
the pellet was resuspended in 2 volumes (v/w) of the same
medium. Cells (1 ml) were labeled for 45 min in 5 mM Glc with
300 Ci/ml [14C]Glc. Half of each labeled sample was washed
with 20 volumes of 1% YNB, centrifuged, and chased for 150
min in 0.5 ml of 1% YNB containing 100 mM glucose, whereas
the other half was processed immediately. Glycoprotein purifi-
cation and glycan pattern analysis of all samples were per-
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formed as described above for NLOs. To determine cell wall
monosaccharide composition, the water-insoluble material
obtained after protease digestion of labeled glycoproteins was
heated for 150 min at 100 °C in 2 N NaOH in a final volume of
2.5 ml, precipitated with 3 ml of methanol, and washed three
times with 75%methanol. Insoluble material was heated for 4 h
at 100 °C in 1 NHCl, dried at room temperature, and submitted
to paper chromatography in Whatman 1 paper with butanol/
pyridine/H2O (10:3:3) as solvent.
Purification of total-cell protein extracts, microsomal
fractions, and protein deglycosylation
Yeast whole-cell extracts were obtained from 20 ml of expo-
nentially growing cultures at A600 nm  2. Cells were washed
once with water, harvested, and broken with glass beads (0.5
mm inner diameter) by 10 repetitive cycles of 1-min vortexing
followed by 1 min on ice in 0.1 M HEPES, pH 7.2, 1% Triton
X-100, 5 mM EDTA with protease inhibitors (100 M phenyl-
methylsulfonyl fluoride, 10 M L-1-tosylamido-2-phenylethyl
chloromethyl ketone, 10 M N-p-tosyl-L-lysine chloromethyl
ketone, 10 M leupeptin, 10 M pepstatin, and 10 M E64), and
cleared by centrifugation at 20,000 g for 20 min. Microsomal
(ER and Golgi-enriched) fractions were obtained as described
previously (31). To measure S. pombe endomannosidase activ-
ity, gls2 microsomal fractions were resuspended in 100 mM
phosphate buffer, pH 6.8, 0.25 M sucrose, 1 mM EDTA, and
protease inhibitors. Protein concentrations were determined
by protein assay as described by Bio-Rad. To obtain deglycosy-
lated extracts, 50 g of whole-cell proteins were denaturalized
with 0.5% SDS and 40 mM DTT at 100 °C, and treated with 1
milliunit of Endo H overnight at 37 °C in 50 mM triethanol-
amine, pH 5.5.
Endomannosidase activity assays
Endomannosidase activity of 100 g of total protein from
microsomal fractions of S. pombe gls2 cells was determined by
incubationwith2000cpmof [glucose-14C]Glc1Man9GlcNAc in50
l of 50 mM sodium phosphate buffer, pH 6.8, 0.5% Triton X-100
for30minat37 °C.Reactionswere stoppedby theadditionof50l
of methanol, incubated for 5 min at 60 °C, and centrifuged for 5
minat15,000 g. Released [14C]Glc-Manand the remainingnon-
hydrolyzedsubstrateof the supernatantwere separatedbyascend-
ingpaper chromatography inWhatman1using2-propanol/acetic
acid/H2O (25:4:9) as solvent. The disaccharide nature of the
released radioactivity was confirmed by ascending paper chroma-
tography using 1-butanol/ethanol/H2O (10:1:2) as solvent and
sucrose, maltose, and Glc as standard.
Immunoblottings
Total S. pombe proteins (50 g) were run in SDS-PAGE and
electrotransferred to Immobilon-P membranes (Millipore)
1.5 h at 100 mA. For detection of the CNX glycosylation status,
the resolving gel was 12%, and the membrane was incubated
first with previously obtained rabbit anti-S. pombe CNX anti-
body (1:10,000) (46) and then with anti-rabbit antibody
(1:3000) conjugated toHRP (Sigma). For STT3D-HAdetection,
the gel was 9%, and the membrane was incubated with rat
anti-HA (1:5000) (Roche Applied Science) followed by anti-rat
conjugated toHRP (1:5000) (Sigma). Bandswere revealed using
West Pico SuperSignal chemiluminescent substrate (Thermo-
Fisher Scientific, Waltham, MA) following the instructions of
the manufacturer. Membranes were developed using an Image
Quant Las4000 luminescent image analyzer.
Transmission electronmicroscopy
WT or gls1-S cells were grown to A600 nm  1 (0.2) and
fixed overnight at room temperature using 2.5% glutaraldehyde
in 0.1 M phosphate buffer, pH 7.4, supplemented with 0.01%
ruthenium red to increase electronic contrast in the cell wall.
This step was followed by post-fixation in 1% osmium tetroxide
for 1 h. Samples were stained overnight at 4 °C in 2% uranyl
acetate and dehydrated with ethanol. Then they were embed-
ded in Epoxy resin (Durcupan), and 60–70-nm sections were
cut. Images were obtained using a transmission electronmicro-
scope (TEM-Zeiss-EM109T) and photographed with a Gatan
ES1000Wdigital camera. Images with a85,000magnification
of 9–12 cells per genotype were taken randomly. The signal
intensities along the cell wall’s cross-sections were obtained
using ImageJ software.
Subcellular localization of expressed hEM
gls1-S orgls2 cells transformed with Golgi hEM fused to
GFP were grown to A600 nm 1 in EMM lacking leucine. Cells
(200 l) were harvested and resuspended in 500 l of YES.
Images were obtained using a Zeiss confocal microscope LSM
710, with a63 Zeiss Plan-Apochromat objective (NA 1.4). At
least 10 images were taken randomly per genotype. For pro-
cessing images, a smooth filter was set using ImageJ software to
improve the quality. For endocytic pathway staining, 20 l of
cultures were incubated with 0.1 mg/ml FM4-64 at 30 °C for 90
min and washed with PBS.
Growth, morphology, and survival of S. pombemutants
Growth of S. pombemutants in solidmediawas performed as
follows: cultures of to-be-compared strains at the early station-
ary phase were diluted to a final concentration of 2 106 cells/
ml. Tenth dilution series in YESwere performed, and drops of 5
l of each dilutionwere spotted in solid YES, in triplicate. Plates
were incubated at 28 °C, and images were taken every 24 h with
an Olympus C-610 digital camera for 5 days.
To perform growth curves of S. pombe mutants in liquid
media, a pre-culture of each S. pombe strain at the end of the
exponential phase was used to start three 50-ml cultures of YES
atA600 nm 0.2 in 250-ml flasks (time 0), which were grown for
5 days at 28 °C with agitation at 250 rpm. Aliquots were taken
every 4 h to monitor OD at 600 nm. Data were analyzed with R
(47) and a logistic adjustment was used.
Survival of S. pombemutants at different stages of the growth
curve was scored by counting colony-forming units from dilu-
tions of aliquots taken at each time point plated on YES and
incubated for 7 days at 28 °C. The proportion of colony forma-
tion units in a population was considered as the percentage of
survival at a given time point. Cell growth curves were per-
formed in independent triplicates for each mutant. ANOVA
statistical analysis was done using Bonferroni’s test.
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Survival was also measured by the ability to exclude the flu-
orescent dye phloxine B (disodium 2,4,5,7-tetrabromo-
4,5,6,7-tetrachlorofluorescein) as follows: for each time point of
the growing curve 1.4  107 cells were incubated in 1 ml of a
final volume of YES with 5 g/ml phloxine B for 2 h at 28 °C
with shaking as described (48). An amount of 10,000 cells were
then analyzed by flow cytometry using a FACSCalibur flow
cytometer (BD Biosciences) with an argon laser (excitation at
488 nm). Emission at 546–550 nm (filter FL2) was monitored
for phloxine B–stained cells that were compared with a non-
stained culture. As a control of stained death-cell fluorescence
intensity, cultures in exponential growth were heated 1 h at
65 °C and analyzed by flow cytometry as described above.
ANOVA statistical analysis was done using Bonferroni’s test.
To measure the cell length of mutant yeasts, images of cul-
tures in exponential phase (A600 nm 1) were acquired using an
Olympus BX60 light transmission microscope with a UPlanFI
100 oil objective (NA 1.30) and an Olympus DP71 camera.
Cell lengths (at least 180 for each mutant) were measured with
ImageJ software. Statistical analyses were done using Bonferro-
ni’s multiple comparison test.
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